About RheumaView™
RheumaView™ is a deterministic radiographic intelligence platform designed by a practicing rheumatologist for the problems that practicing clinicians, researchers, and pharmaceutical sponsors actually face — and that existing imaging tools have failed to solve.
The platform was not born in a computer science lab optimizing for benchmark accuracy. It was born in clinical practice, where the same radiograph interpreted by different readers on different days produces different reports, different severity assessments, and different downstream decisions.
That variability is not a minor nuisance. In clinical trials, it undermines endpoint integrity. In longitudinal care, it erodes the ability to track true structural change. In regulatory environments, it creates audit risk. And in research, it makes imaging data unreliable as a quantitative source.
RheumaView™ was built to eliminate that variability at the architectural level.
The Founder
RheumaView™ was designed by a board-certified rheumatologist and independent researcher whose clinical experience — interpreting musculoskeletal imaging across inflammatory, degenerative, metabolic, and pediatric conditions — exposed a fundamental gap between what imaging could deliver and what current tools actually produce.
The platform is the result of that insight: a system where every output is governed by a fixed validation pathway, where clinical and research layers are structurally separated, and where reproducibility is not a marketing claim but an architectural constraint.
What the Platform Is Not
RheumaView™ is not a radiology chatbot. It is not a probabilistic classifier with a confidence score. It is not a single-task detection tool wrapped in a platform label.
It is a multi-domain, validator-governed radiographic architecture with a clinical rendering layer, a research analytics layer, and a growing family of specialty extensions — all operating under deterministic, auditable, lineage-preserved logic.
Intellectual Property
The platform is protected by a patent portfolio currently under USPTO prosecution, including a Track One prioritized non-provisional application and multiple planned continuation applications covering independent inventive domains.
Public materials — including scientific publications, case illustrations, and this site — are deliberately calibrated to establish scientific priority and demonstrate capability without disclosing proprietary implementation.
Scientific Foundation
RheumaView™ is supported by a growing body of published preprints across multiple platforms, establishing the methodological, architectural, and clinical foundations of the system. Publications are listed on the Publications page of this site.
Contact
For scientific collaboration, clinical trial partnership, investment discussion, or general inquiries:
info@rheumaview.com
